Ardelyx Q2 Revenue Jumps 33%
(NASDAQ:ARDX), a biopharmaceutical company focused on gastrointestinal and cardiorenal therapeutics, reported its second quarter 2025 earnings on August 4, 2025. The headline news was a major revenue beat, with $97.7 million GAAP revenue reported for Q2 2025 compared to the $81.08 million analyst consensus (GAAP). Loss per share (GAAP) narrowed to $(0.08), outpacing the $(0.13) GAAP EPS expected. The company saw strong performance from its IBSRELA product, which grew sales by 84% year over year, and raised guidance for that drug’s outlook in FY2025. Overall, it was a quarter marked by top-line strength and evidence that Ardelyx’s commercialization strategy is delivering results, though the company remains in a loss-making position as it continues to invest heavily in commercial expansion.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
(NASDAQ:ARDX) specializes in developing and commercializing treatments for patients with gastrointestinal and kidney-related diseases. Its business centers on two primary drugs: IBSRELA, a prescription tablet for adults with irritable bowel syndrome with constipation (IBS-C), and XPHOZAH, a phosphate absorption inhibitor for adults with chronic kidney disease (CKD) on dialysis. Both drugs use the proprietary compound tenapanor, and the company maintains patents on this key ingredient through 2033–2034.
Source Fool.com
